Neurology

Neurology

Home News Diseases Conferences Special Reports

parkinson's%20disease%20-and-%20parkinson's%20disease%20dementia

PARKINSON'S DISEASE & PARKINSON'S DISEASE DEMENTIA

Parkinson's disease is a progressive neurodegenerative disorder that is common, age-related and chronic.

It is caused by loss or degeneration of dopaminergic neurons in the substantia nigra of the midbrain.

Onset of symptoms and progression of the disease is gradual.

Motor signs and symptoms include resting tremor, rigidity, bradykinesia and postural instability.

Parkinson's disease dementia indicates loss of intellectual functions including memory, significant deterioration in the ability to carry out day-to-day activities and changes in social behavior are often noted.

Parkinson's%20disease%20-and-%20parkinson's%20disease%20dementia Patient Education

Patient Education

Educate the patient on the nature of the illness, its treatment, etc

Lifestyle Modification

Exercise

May improve function
Prevent falls and improve mobility
Upright posture and gait training
Extension exercise of neck, trunk and legs
- Formal exercise program where home exercises are performed daily
- Refresher exercise every 6-12 months

Nutrition

Gastrointestinal musculature impairment may cause swallowing and chewing difficulties
Gastrointestinal disturbances due to prescribed medications may occur
Assist patient in maintaining proper nutritional status through balanced diet and good eating habits
- Nutritional supplements may be given if required

Product Highlight - Pontevia

16 Mar 2022

Galcanezumab Injection

Shifting paradigms in MS management: Early, optimized interventions improve patient outcomes

04 May 2018

Multiple sclerosis (MS) is one of the most common neurological disorders – affecting over 2.3 million people globally – and it is the leading cause of nontraumatic disability in young adults. However,the availability of supportive resources and services for people with MS is scarce in many regions of the world. In Malaysia, the prevalence of MS is estimated at 2-3/100,000; the current Malaysian clinical practice guidelines on the management of MS recommend disease modifying agents, such as interferon-β and teriflunomide, as first-line therapeutic agents. In this article, Dr Singer - in partnership with Sanofi and the Malaysian Society of Neurosciences - shares his insights into managing MS dynamically, highlighting the importance of early intervention in improving patient outcomes.